Publications

Therapeutic drug monitoring

Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.

PDA journal of pharmaceutical science and technology

Pharmaceutical development of a parenteral lyophilised dosage form for the novel anticancer agent C1311.

Molecular and cellular biology

Association of BMI1 with polycomb bodies is dynamic and requires PRC2/EZH2 and the maintenance DNA methyltransferase DNMT1.

Trends in pharmacological sciences

An emerging role for PtdIns(4,5)P2-mediated signalling in human disease.

Cancer cell

Mitogen requirement for cell cycle progression in the absence of pocket protein activity.

Current gene therapy

Prospects and limitations of T cell receptor gene therapy.

Cell cycle (Georgetown, Tex.)

CDK-dependent stabilization of Cdc6: linking growth and stress signals to activation of DNA replication.

British journal of cancer

Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours.

28-11-2005

Oncogene

Retroviral insertional mutagenesis: past, present and future.

21-11-2005

Rapid communications in mass spectrometry : RCM

Simultaneous quantification of fludarabine and cyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

16-11-2005

International journal of radiation oncology, biology, physics

Automatic prostate localization on cone-beam CT scans for high precision image-guided radiotherapy.

15-11-2005

Methods in enzymology

Functional annotation of deubiquitinating enzymes using RNA interference.

09-11-2005

Nature cell biology

The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene.

The Journal of pharmacology and experimental therapeutics

Coformulated N-octanoyl-glucosylceramide improves cellular delivery and cytotoxicity of liposomal doxorubicin.

European journal of cancer (Oxford, England : 1990)

Quality of life among long-term breast cancer survivors: a systematic review.

Breast cancer research and treatment

Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy.

Clinical pharmacokinetics

Clinical pharmacokinetics of cyclophosphamide.

20-10-2005

British journal of cancer

No common denominator for breast cancer lymph node metastasis.

17-10-2005

PDA journal of pharmaceutical science and technology

Pharmaceutical development of a parenteral lyophilised formulation of the investigational anticancer agent ES-285.HCl.

13-10-2005

Nederlands tijdschrift voor geneeskunde

[Rapid tracing of new patients with cancer through the nationwide network and registry of histo- and cytopathology in the Netherlands (PALGA) in order to freeze tumour material for molecular-epidemiological research].

Cell cycle (Georgetown, Tex.)

p16INK4a as a second effector of the telomere damage pathway.

Anti-cancer drugs

Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.

Cancer investigation

Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application.

Cancer chemotherapy and pharmacology

Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism.

Cancer chemotherapy and pharmacology

Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer.

Investigational new drugs

Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer.

Cell

The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling.

23-09-2005

International journal of cancer

MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid.

20-09-2005

Cancer research

Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development

15-09-2005

Menopause (New York, N.Y.)

Are cause of subfertility and in vitro fertilization treatment risk factors for an earlier start of menopause?

08-09-2005

Cancer immunology, immunotherapy : CII

Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study.

Genome research

Genome-wide HP1 binding in Drosophila: developmental plasticity and genomic targeting signals.

EMBO reports

Ablation of the spindle assembly checkpoint by a compound targeting Mps1.

Journal of pharmaceutical and biomedical analysis

Development and validation of an LC-UV method for the quantification and purity determination of the novel anticancer agent C1311 and its pharmaceutical dosage form.

The oncologist

Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa).

Stem cells (Dayton, Ohio)

Contribution of the ABC transporters Bcrp1 and Mdr1a/1b to the side population phenotype in mammary gland and bone marrow of mice.

Cancer chemotherapy and pharmacology

Metabolism of docetaxel in mice.

The oncologist

Development of farnesyl transferase inhibitors: a review.